- About us
- About Vaccines
- Media centre
- Become a member
Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.
Effective vaccination programmes ease pressure on budgets and allow resources to focus on other healthcare areas and medical innovation
Vaccination at the Heart of Public Health. Vaccines Europe calls on EU policy-makers to develop a comprehensive vaccination strategy through five core policy asks.
As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe as well as small and medium sized enterprises.
Find out more about our services, the opportunites we offer and how to become a member.
Vaccines Europe is pleased to announce that Pascale Mauran, Vice-President, IDM Vaccines Commercial Development at Pfizer, has been officially appointed as the new Vaccines Europe President. Pascale Mauran has been representing Pfizer on the Vaccines Europe Board for four years now, out of which one and half year as Vaccines Europe Vice-President. She brings solid experience and expertise on vaccines to help drive the development of the Vaccines Europe objectives. Pascale Mauran’s appointment as President will start immediately and will run for the next two years.
Pascale Mauran stated: “I am delighted to take the responsibility of President of Vaccines Europe and continue to drive Vaccines Europe strategy and vision in this significant momentum for vaccination in Europe with the EU Joint Action on Vaccination and all other important EU initiatives underway”.
Vaccines Europe expresses its gratitude to its former President Andrea Rappagliosi, for his strong leadership dedicated to Vaccines Europe over the past 5 years.
For more information, please contact:
Magdalena R. de Azero, Executive Director, Vaccines Europe
Vaccines Europe welcomes the European Commission initiative to launch the EU Joint Action on Vaccination. This EU Joint Action represents a unique opportunity to address common challenges faced by the EU Member States as highlighted in the Council Conclusions on vaccinations as an effective tool in public health, in December 2014. This becomes even more relevant against a background of increasing vaccine-preventable disease outbreaks leading to avoidable death and disability, the increase of antimicrobial resistance and the ageing of the population.
The vaccine industry shares the commitment of the entire public health community to protect European citizens of all ages against infectious diseases. Vaccines Europe is committed to working with stakeholders to ensure a reliable supply of safe, effective and innovative vaccines in Europe and worldwide. Vaccines Europe has identified a number of key areas, which could significantly strengthen vaccination in Europe and facilitate the achievements of European Immunisation goals.
Access and download our paper here.
24-30 April 2017: This week is the European Immunisation Week (EIW2017) that is being celebrated across the European Region. Under the slogan “Vaccines work” the EIW 2017 will focus on the need for and benefits of immunisation at every stage in life.
It is well acknowledged that childhood vaccination is one of the most important medical achievements of the 20th Century. The WHO estimates that vaccination prevents 2-3 million deaths every year across the Globe, and has enormous positive impacts on healthcare systems. However, vaccine-preventable diseases also have significant impacts on adult mortality, health and quality of life. By 2050, the world’s population aged 60 years and older is expected to reach 2 billion, an increase from 900 million today. Increased longevity and lower birth rates are dramatically changing demography in Europe and around the world. With the ageing population, the public health impact of vaccine preventable diseases and their complications in adults are likely to grow.